A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
✍ Scribed by Sen H. Zhuang; Manish Agrawal; Maureen Edgerly; Susan Bakke; Herb Kotz; Paul Thambi; Ann Rutt; Frank M. Balis; Susan Bates; Tito Fojo
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 86 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND
The epothilones are a novel class of microtubule‐stabilizing agents. Ixabepilone (BMS‐247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B. The authors conducted a Phase I study by administering ixabepilone to patients as a 1‐hour intravenous infusion daily for 3 consecutive days every 21 days.
METHODS
Twenty‐six patients were enrolled and received ixabepilone at a starting dose of 8 or 10 mg/m^2^ per day for 3 consecutive days.
RESULTS
One hundred and nineteen cycles were administered to 26 patients. The maximum‐tolerated dose was 8 mg/m^2^ per day of ixabepilone administered as a 1‐hour intravenous infusion daily for 3 consecutive days every 21 days. The dose‐limiting toxicity (DLT) was neutropenia. Other nonhematologic Grade 3 toxicities included fatigue (3 cycles), hyponatremia (1 cycle), anorexia (1 cycle), ileus (1 cycle), stomatitis (1 cycle), and emesis (1 cycle). Prolonged disease stabilization was observed in patients with mesothelioma, ovarian carcinoma, and renal cell carcinoma.
CONCLUSIONS
The recommended Phase II dose of ixabepilone on the daily schedule for 3 days was 8–10 mg/m^2^ per day. Neutropenia was the DLT. Peripheral neuropathy was mild, even after multiple cycles of therapy, and was not dose limiting. Cancer 2005. Published 2005 by the American Cancer Society.